131 related articles for article (PubMed ID: 12110497)
21. Concurrent chemobiotherapy with cisplatin, dacarbazine, decrescendo interleukin-2 and interferon alpha2b in patients with metastatic melanoma.
Bar J; Yerushalmi R; Shapira-Frummer R; Kutchuk I; Sulkes A; Gutman H; Catane R; Schachter J
Oncol Rep; 2008 Dec; 20(6):1533-8. PubMed ID: 19020738
[TBL] [Abstract][Full Text] [Related]
22. Enrollment in clinical trials correlates with improved survival in metastatic melanoma.
Seetharamu N; Tu TJ; Christos P; Ott PA; Berman RS; Shapiro RL; Osman I; Pavlick AC
Oncology; 2011; 81(5-6):403-9. PubMed ID: 22270052
[TBL] [Abstract][Full Text] [Related]
23. LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951).
Agarwala SS; Keilholz U; Gilles E; Bedikian AY; Wu J; Kay R; Stein CA; Itri LM; Suciu S; Eggermont AM
Eur J Cancer; 2009 Jul; 45(10):1807-14. PubMed ID: 19419855
[TBL] [Abstract][Full Text] [Related]
24. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
González Cao M; Malvehy J; Martí R; Conill C; Sánchez M; Martín M; Carrera C; Herrero J; Gascón P; Mellado B; Castel T; Puig S
Melanoma Res; 2006 Feb; 16(1):59-64. PubMed ID: 16432457
[TBL] [Abstract][Full Text] [Related]
25. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model.
Schmidt H; Bastholt L; Geertsen P; Christensen IJ; Larsen S; Gehl J; von der Maase H
Br J Cancer; 2005 Aug; 93(3):273-8. PubMed ID: 16052222
[TBL] [Abstract][Full Text] [Related]
26. Swinging for the Fences: Long-Term Survival With Ipilimumab in Metastatic Melanoma.
Gibney GT; Atkins MB
J Clin Oncol; 2015 Jun; 33(17):1873-7. PubMed ID: 25964248
[TBL] [Abstract][Full Text] [Related]
27. Potential of interferon-alpha in solid tumours: part 1.
Decatris M; Santhanam S; O'Byrne K
BioDrugs; 2002; 16(4):261-81. PubMed ID: 12196039
[TBL] [Abstract][Full Text] [Related]
28. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
Legha SS
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
[TBL] [Abstract][Full Text] [Related]
29. Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b.
Rosenberg SA; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Seipp CA; Einhorn JH; White DE; Steinberg SM
J Clin Oncol; 1999 Mar; 17(3):968-75. PubMed ID: 10071291
[TBL] [Abstract][Full Text] [Related]
30. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
31. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
Khan MA; Andrews S; Ismail-Khan R; Munster PN; Brem S; King J; Reintgen DS; Sondak VK; Daud AI
Cancer Control; 2006 Jul; 13(3):211-7. PubMed ID: 16885917
[TBL] [Abstract][Full Text] [Related]
32. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
Flaherty LE; Atkins M; Sosman J; Weiss G; Clark JI; Margolin K; Dutcher J; Gordon MS; Lotze M; Mier J; Sorokin P; Fisher RI; Appel C; Du W
J Clin Oncol; 2001 Jul; 19(13):3194-202. PubMed ID: 11432886
[TBL] [Abstract][Full Text] [Related]
33. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
[TBL] [Abstract][Full Text] [Related]
34. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
Tarhini AA; Kirkwood JM; Gooding WE; Cai C; Agarwala SS
J Clin Oncol; 2007 Sep; 25(25):3802-7. PubMed ID: 17761969
[TBL] [Abstract][Full Text] [Related]
35. Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
Koyanagi K; O'Day SJ; Gonzalez R; Lewis K; Robinson WA; Amatruda TT; Wang HJ; Elashoff RM; Takeuchi H; Umetani N; Hoon DS
J Clin Oncol; 2005 Nov; 23(31):8057-64. PubMed ID: 16258104
[TBL] [Abstract][Full Text] [Related]
36. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
[TBL] [Abstract][Full Text] [Related]
37. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
[TBL] [Abstract][Full Text] [Related]
38. The role of interleukin-2 in the management of stage IV melanoma: the EORTC melanoma cooperative group program.
Keilholz U; Eggermont AM
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S99-103. PubMed ID: 10685668
[TBL] [Abstract][Full Text] [Related]
39. Ten-year outcomes of a randomised trial for locoregionally advanced nasopharyngeal carcinoma: A single-institution experience from an endemic area.
Huang PY; Zeng Q; Cao KJ; Guo X; Guo L; Mo HY; Wu PH; Qian CN; Mai HQ; Hong MH
Eur J Cancer; 2015 Sep; 51(13):1760-70. PubMed ID: 26093812
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.
Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim K; Hwu WJ; McIntyre S; Hwu P
Cancer Invest; 2008 Jul; 26(6):624-33. PubMed ID: 18584354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
